Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Systemic Therapy
100%
Androgen Deprivation Therapy
100%
Cost-effectiveness Analysis
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Docetaxel
76%
Abiraterone
46%
Abiraterone Acetate
15%
Survival Benefit
15%
Incremental Cost-effectiveness Ratio
15%
Metastatic Prostate Cancer
15%
Disease Progression
7%
Cost-effectiveness
7%
Randomized Trial
7%
Castration-resistant Prostate Cancer
7%
Treatment Options
7%
Prostate Radiotherapy
7%
Measurement Analysis
7%
Statistical Analysis
7%
Epidemiological Data
7%
Quality-adjusted Life Years
7%
Life Cost
7%
Health Sector
7%
Cost-effective Treatment
7%
Quality-adjusted Survival
7%
Natural Progression
7%
State Transition Model
7%
Publication of Results
7%
Private Payer
7%
Standard Costs
7%
Sectors Perspectives
7%
Cost-effective Alternatives
7%
Treatment Benefit
7%
Cost-effectiveness Metrics
7%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Systemic Therapy
100%
Prostate Cancer
100%
Androgen Deprivation Therapy
100%
Docetaxel
76%
Abiraterone
46%
Incremental Cost-Effectiveness Ratio
15%
Abiraterone Acetate
15%
Quality Adjusted Life Year
7%
Epidemiological Data
7%
Outcome Assessment
7%
Cancer Therapy
7%
Castration Resistant Prostate Cancer
7%
Diseases
7%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Docetaxel
76%
Abiraterone
46%
Abiraterone Acetate
15%
Castration Resistant Prostate Cancer
7%
Diseases
7%